ArriVent Appoints Chris Nolet to its Board of Directors
NEWTOWN SQUARE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Chris Nolet to its Board of Directors.
- NEWTOWN SQUARE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Chris Nolet to its Board of Directors.
- “The addition of Chris Nolet to our Board of Directors comes at an important time for ArriVent as we advance our global development plans for furmonertinib in non-small cell lung cancer, including an ongoing Phase 3 study, and continue to broaden our pipeline,” said Bing Yao, Chairman, Co-founder and Chief Executive Officer of ArriVent.
- “Chris has worked with a wide range of life science companies, from rapidly growing startups to Fortune 100 multinational organizations.
- Previously, Mr. Nolet was a member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization.